SPECIAL NOTICE

We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.

SEARCH BY NAME

BROWSE

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH BY CODE

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

CANN GLOBAL LIMITED (CGB)

Listed on ASX

SHARE PRICES

(updated at weekends)

Former (or subsequent) names

Shareholder links

Our website ranking of CGB: rating 5
(5 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare, Level 3, 60 Carrington Street, Sydney NSW 2000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000038085
Address: Level 21, 133 Castlereagh Street, SYDNEY NSW 2000
Tel:  +61 (0)2 8379 1832 Fax: 02-9291-9099

Date first listed: 14/01/2008
Company Secretary: Alex Neuling
Sector: Pharmaceuticals Biotechnology & Life Sciences Industry Group: XMJ
Activities: Medical cannabis/mining

The suspension of trading in the securities of Cann Global Limited will be lifted immediately, following the release by CGB of an announcement regarding current research initiatives.

15/06/2020

Successful in vitro and in vivo trials to stop the progression of MS using a unique cannabis strain. In some cases, the damage was also significantly reversed. The Technion has found a chemovar that can effectively kill CD4 T cells that have become destructive instead of productivev, which causes the damange to the body by the immune system in MS. The Technion is isolating and identifying the molecules within the strain that is responsible for the therapeutic effect, withe the goal of creating a pharmaceutical product to safely treat MS without the detrimental side effects found in current MS treatments. The company is now engaging with the Tecchnion to plan concurrent clinical trials to test the same chemovar on other damanging immune malfunctions that can be caused by destructive T cells in other diseases. Clinical trials in Israel using whole Cannabis extracts are very different from traditional pharmaceutical clinical trials and do not require phase 1 of safety and toxicity.

15/06/2020

The company provides an update on issues with SUN and COVID-19 delays. The company has entered a new cultivation agreement with AA Bio Co Ltd. Purchase orders were received for a total value of USD $750,000.

15/06/2020

The Company is still in discussions with the ASX finalising the announcement and is not yet in a position to make the announcement at this time, and requests an extension to the current voluntary suspension, pending release of an announcement by the Company regarding current research initiatives. It is expected that the announcement will be able to be made by Monday 15 June 2020.

11/06/2020

CGB requests a further extension to the current voluntary suspension, pending release of an announcement by the Company regarding current research initiatives, as referenced in the Company's original trading halt request. It is expected that the announcement will be able to be made by Friday 5 June 2020.

03/06/2020

CGB requests a further extension to the current voluntary suspension, pending release of an announcement by the Company regarding current research initiatives. It is expected that the announcement will be able to be made by Tuesday 2 June 2020.

28/05/2020

The Company is still in discussions with the ASX and is not yet in a position to make the announcement at this time, and requests an extension to the current voluntary suspension, pending release of an announcement by the Company regarding current research initiatives. The announcement is expected to be made by 27 May 2020.

25/05/2020

The securities of Cann Global Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CGB, pending the release of an announcement regarding current research initiatives.

20/05/2020

The suspension of trading in the securities of Cann Global Limited will be lifted immediately following the release by CGB of an announcement regarding an institutional investment into CGB.

19/03/2020

The company releases a notice of Proposed issue of Securities - CGB.

19/03/2020

The company has entered into agreements for the refinancing of the convertible notes currently on issue through an assignment and variation arrangement between the company, L1 Capital Global Opportunities Master Fund and Obsidian Global GP, whereby Obsidian has agreed to buy out the convertible notes from L1. Upon L1 receiving the funds from Obsidian, L1 has agreed to re-invest a further $862,000 into the company by way of a placement of $250,000 for 25,000,000 new shares at 1c per share and $612,000 in return for 680,000 new convertible notes issued jointly by CGB and CGB's wholly owned subsidiary Medical Cannabis Research Group Pty Ltd to be repaid in the first instance by MCRG in 8 months from the issue date, or otherwise by CGB. Proceeds from the capital raising are expected to be applied towards furthering the commercialisation of the MS research being undertaken by MCRG in conjunction with the Technion in Haifa, Israel, and for general working capital.

19/03/2020

The company requests an extension to the current voluntary suspension, pending an announcement regarding institutional investment into the company. The announcement is expected to be made by 23 March 2020.

19/03/2020

The securities of Cann Global Limited will be suspended from quotation immediately under Listing Rule 17.2, at the request of CGB, pending the release of an announcement regarding an institutional investment into CGB.

17/03/2020

The suspension of trading in the securities of Cann Global Limited (formerly Queensland Bauxite Limited) will be lifted from the commencement of trading on Friday, 23 August 2019, following CGB's re-compliance with Chapters 1 and 2 of the Listing Rules.

22/08/2019

The suspension of trading in the securities of Cann Global Limited is expected to lift and the company reinstated to official quotation at the commencement of trading on Friday 23 August 2019, following its re-compliance with Chapters 1 and 2 of the ASX Listing Rules. The Company raised $5,950,000 pursuant to the offer under its replacement prospectus dated 7 June 2019 by the issue of 170,000,000 shares at an issue price of $0.035 per share and 85,000,000 free attaching options exercisable at $0.10 each on or before 30 April 2020.

21/08/2019

ASX have received confirmation that the final documents are now en route via courier from overseas. Upon receipt of these documents by the ASX to satisfy the remaining relisting conditions, a formal relisting notice with the exact relisting date and time will be issued on the ASX announcements platform. CGB therefore anticipates that its securities will be reinstated to trading on the ASX mid to late next week.

16/08/2019

The public offer for 170,000,000 shares to raise $5,950,000 closed fully subscribed. All conditions to the public offer have been satisfied. The offers have closed and all issues of securities under the offers have been completed. CGB confirms that all conditions precedent to the agreements between the company and the vendors of MCL, T12 and HHC have been satisfied and the agreements have been completed.The Board looks forward to the relisting of the company's shares to trading on the ASX.

09/08/2019

The company is in the process of providing the ASX with all the paperwork confirming completion of all the transactions, completion of all the share issues, receipt of all the required escrow agreements, and the related required relisting documentation.

10/07/2019

The company releases the results of its general meeting.

02/07/2019

The company releases a replacement prospectus for an offer of up to 170,000,000 new shares at an issue price of $0.035 per share to raise up to $5,950,000, with a minimum subscription of $1,995,000 together with one (1) free attaching option for every two (2) shares subscribed for and issued.

11/06/2019

During cultivation trials of the various Cannabis cultivars, Andrew Kavasilas, MCL's Technical Director, reported that he had identified the very rare and unique "˜Triploid' characteristic in a particular species of Cannabis plant. As part of Stage 1 of the "˜Tabulum Project', the Research Division of MCL, are happy to report on the outdoor results from the Triploid Trial Crops which continue to be assessed as part of a two (2) year seasonal crop rotation program. Cann Global looks forward to presenting the market and its shareholders the results of the Stage 2 "˜Tabulum Project' in early 2020.

07/06/2019

The company releases a notice of general meeting. The meeting will be held at 1pm (EST) on 2 July 2019 at Level 16, 1 Market St Sydney, NSW.

31/05/2019

On 24 May, the company lodged a supplementary prospectus with two typographical errors left over from an earlier prospectus template where in two places it referred to this "ninth" supplementary instead of referring to this "fifteenth" supplementary. The amended version will be sent to well over 1,000 current applicants.

27/05/2019

The company lodges its Half Year Accounts.

24/05/2019

The company issues a fifteenth supplementary prospectus.

24/05/2019

ASX has confirmed that based solely on the information contained in the recent extensive and detailed documentation and correspondence between the company and the ASX, nothing has come to ASX's attention: that would cause ASX to exercise its discretion to refuse admission to the official list under listing rule 1.19; and that would cause ASX to determine that the company's proposed structure and operations are not suitable for a listed entity for the purposes of listing rule 1.1 condition 1. The company will now progress with the relisting process.

15/05/2019

The company issues a fourteenth supplementary prospectus.

18/04/2019

The company issues a thirteenth supplementary prospectus.

22/03/2019

The company issues an twelfth supplementary prospectus.

22/02/2019

The company issues an eleventh supplementary prospectus.

08/02/2019

A materially strategic MOU has been entered into with Biohealth Pharmaceuticals. This strategic alliance will assist Cann Global Limited to move its production schedule of Medical Cannabis formulations and nutraceutical Hemp Food consumables forward to 1H 2019, focusing on potentially lucrative short-term revenues to further establish CGB in the emerging Cannabis industries.

08/02/2019

The company lodges its Quarterly Activities and Cashflow Report.

01/02/2019

The company issues a supplementary prospectus.

25/01/2019

name changed from Queensland Bauxite Limited

25/01/2019

ASX Announcements (courtesy of ASX)

 

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...


    Directors' on-market share transactions (last 5)

     

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Pnina FeldmanChairman12/04/2007
    Sholom FeldmanCEO09/11/2007
    Marion LesaffreCOO28/08/2020
    Jonathan CohenIndependent Director02/07/2019
    David AustinIndependent Director15/04/2008
    John EasterlingIndependent Director02/07/2019

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Meyer GutnickNon Exec Director04/03/201402/07/2019
    Paul StephensonNon Exec Director07/10/200804/03/2014
    Russell WilliamsNon Exec Director18/04/201107/02/2014

    Date of first appointment, title may have changed.